HAE

Haemonetics Corporation

84.87 USD

Last updated Dec 10, 17:31 UTC

Yesterday HIGH

$84.89

Yesterday LOW

$82.8

52w HIGH

$95.26

52w LOW

$72.26

EPS

0.99

PE

85.73

Next Earnings

Feb 6, 2024

Overview News Government Trades

Haemonetics Corporation stock is down -1.45% since 30 days ago. The next earnings date is Feb 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 56.67% of the previous 29 December’s closed higher than November.

Haemonetics Corporation provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software. It also provides automated blood component and manual whole blood collection systems.

Stock Exchange

NYSE

Sector

Manufacturing

Industry

Medical Equipment

Headquarters

Braintree, United States Of America

Website

haemonetics.com

Benzinga Newsdesk

Thu May 11, 2023

Haemonetics Q4 EPS $0.77 Beats $0.70 Estimate, Sales $304.42M Beat $289.64M Estimate

Haemonetics (NYSE:HAE) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $0.70 by 10 percent. This is a 18.46 percent increase over earnings of $0.65 per share from the same
Benzinga Newsdesk

Wed Feb 8, 2023

Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $88

Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $84 to $88.
Benzinga Newsdesk

Wed Feb 8, 2023

Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $95

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Neutral and raises the price target from $92 to $95.
Benzinga Insights

Wed Feb 8, 2023

Looking Into Haemonetics's Return On Capital Employed
Lisa Levin

Wed Feb 8, 2023

Alphabet To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Wednesday

Loop Capital boosted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $120 to $125. Loop Capital analyst Rob Sanderson maintained a Buy rating. Alphabet shares fell 3.7% to $103.70 in pre-market trading.
Benzinga Newsdesk

Wed Feb 8, 2023

Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $103

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $94 to $103.
Benzinga Newsdesk

Wed Feb 8, 2023

Mizuho Maintains Buy on Haemonetics, Raises Price Target to $115

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $110 to $115.
Benzinga Newsdesk

Tue Feb 7, 2023

Haemonetics Raises FY23 Adj EPS Outlook from $2.70 - $3.00 to $2.90 - $3.00 Vs. $2.79 Est.
Benzinga Newsdesk

Tue Feb 7, 2023

Haemonetics Raises FY23 Sales Growth Guidance From 15% - 18% to 18% - 20%
Benzinga Newsdesk

Tue Feb 7, 2023

Haemonetics Q3 Adj EPS $0.85 Beats $0.80 Estimate, Sales $305.30M Beat $300.47M Estimate

Haemonetics (NYSE:HAE) reported quarterly adjusted earnings of $0.85 per share which beat the analyst consensus estimate of $0.80 by 6.25 percent. This is a 1.19 percent increase over earnings of $0.84 per share from the